Search

BOSTON -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced management participation in two upcoming investor conferences. * Dr. Reshma Kewalramani, Chief Executive Officer and President, will participate in a fireside [...]

- New data on povetacicept 80 mg SC Q4 weeks in IgA nephropathy shows mean UPCR reduction from baseline of 66% observed at 48 weeks, associated with stable renal function [...]

- Phase 3 data on investigational vanza triple demonstrates non-inferiority to TRIKAFTA([R]) in ppFEV1 and further improvement of CFTR function as measured by sweat chloride - - Real-world evidence and [...]

BOSTON -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced management participation in two upcoming investor conferences. * Dr. Reshma Kewalramani, Chief Executive Officer and President, and Charles Wagner, Executive Vice [...]

NEWTON, Mass. -- The RMR Group (Nasdaq: RMR) today announced the early renewal of the Vertex Pharmaceuticals Incorporated ('Vertex') lease for 1.1 million square feet of office and laboratory space [...]

- FDA grants priority review and assigns a Prescription Drug User Fee Act (PDUFA) target action date of January 30, 2025 - - Suzetrigine, an investigational non-opioid pain signal inhibitor, [...]

Orum to receive a $15 million upfront payment and up to $310 million in potential option fees and milestone payments per target plus tiered royalties BOSTON & DAEJEON, South Korea [...]

- Vanza triple granted priority review with Prescription Drug User Fee Act (PDUFA) target action date of January 2, 2025 - - EU Marketing Authorization Application (MAA) submission also validated [...]

- Results from a randomized, placebo-controlled study of TRIKAFTA([R]) in people with cystic fibrosis with rare, non-F508del CFTR mutations showed statistically significant and clinically meaningful improvements in the primary and [...]

BOSTON -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced management participation in two upcoming investor conferences. * Dr. Reshma Kewalramani, Chief Executive Officer and President, will present at the William [...]

M2 PRESSWIRE-May 15, 2024-: Cystic Fibrosis Pipeline, FDA Approvals, Unmet Needs, Preclinical and Discovery Stage Product, and Companies 2024 (Updated) (C)1994-2024 M2 COMMUNICATIONS RDATE:14052024 DelveInsight's, 'Cystic Fibrosis Pipeline Insight 2024' [...]

- Rolling submission for suzetrigine moderate-to-severe acute pain NDA granted by FDA; first module submitted and on track to complete filing this quarter - - Successful completion of end-of-phase 2 [...]

-- Povetacicept administered subcutaneously once every four weeks continues to be well tolerated in IgA nephropathy, with UPCR reductions of greater than 60% observed at 36 weeks, associated with remission, [...]

- Alpine is a clinical stage biotechnology company focused on discovering and developing innovative, protein-based immunotherapies - - Alpine's lead product, povetacicept, demonstrated best-in-class potential in patients with IgA nephropathy [...]

BOSTON -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Charles Wagner, Executive Vice President and Chief Financial Officer, and David Altshuler, M.D., Ph.D., Executive Vice President, Global Research, and [...]

Mayor Michelle Wu announced the recipients of $4.7 million in funding to train and place Boston residents into life sciences careers, the latest stage of the Citys Life Sciences Workforce [...]

BOSTON -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Dr. Reshma Kewalramani, Chief Executive Officer and President, will present at the 42nd Annual J.P. Morgan Healthcare Conference on Monday, [...]

- If approved by the European Commission, patients 12 years of age and older with severe sickle cell disease or transfusion-dependent beta thalassemia, for whom hematopoietic stem cell transplantation is [...]

- First-ever approval of a CRISPR-based gene-editing therapy in the U.S. - - Approximately 16,000 patients 12 years of age and older with severe sickle cell disease may now be [...]

(GLOBE NEWSWIRE via COMTEX) -- MANAMA, Bahrain, Dec. 02, 2023 (GLOBE NEWSWIRE) -- Bahrain has become the second country in the world and the first in the Middle East to [...]

(GLOBE NEWSWIRE via COMTEX) -- RoslinCT to manufacture exagamglogene autotemcel (exa-cel) for Vertex Pharmaceuticals Inc following an extensive development collaboration RoslinCT will manufacture world's-first CRISPR-based therapy EDINBURGH, UK, 28 November [...]

Earlier today, UK's Medicines and Healthcare products Regulatory Agency (MHRA) granted conditional marketing authorization to Vertex Pharmaceuticals and CRISPR Therapeutics for their CRISPR/Cas9 gene therapy, CASGEVY (exagamglogene autotemcel), marking the [...]

London: Imperial College London, South Kensington Campus has issued the following news release: The UK has become the first country in the world to approve a gene therapy as a [...]

- First regulatory authorization of a CRISPR-based gene-editing therapy in the world - - CASGEVY is indicated for the treatment of sickle cell disease in patients 12 years of age [...]

- New data including longer duration follow-up from SCD and TDT pivotal trials accepted for oral presentation - - Five additional abstracts accepted for poster presentation - BOSTON -- Vertex [...]

BOSTON -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that data on TRIKAFTA([R]) (elexacaftor/tezacaftor/ivacaftor and ivacaftor), which can treat the underlying cause of cystic fibrosis (CF) in ~90% of people [...]

The Cellular, Tissue, and Gene Therapies Advisory Committee of the FDA is meeting tomorrow, Tuesday, October 31, 2023, to review a Biologics License Application by Vertex Pharmaceuticals Inc. for exagamglogene [...]

Former AstraZeneca and Vertex Pharmaceuticals executive bolsters agency's Value, Access, and Reimbursement practice NEW YORK & TORONTO -- Klick Health today announced that admired market access professional Ellen Cappellino has [...]

BOSTON -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced management participation in two upcoming investor conferences. * Charles Wagner, Executive Vice President and Chief Financial Officer, and David Altshuler, M.D., [...]

FRAMINGHAM, Mass. -- The TJX Companies, Inc. (NYSE: TJX), the leading off-price apparel and home fashions retailer in the U.S. and worldwide, announced today that on September 20, 2023, its [...]

- Paul Negulescu, Fredrick Van Goor and Sabine Hadida receive Breakthrough Prize for developing transformative medicines for people with cystic fibrosis - BOSTON -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today [...]

Vertex Pharmaceuticals reported that the European Medicines Agency (EMA) has validated a Type II variation application to the Marketing Authorization for KAFTRIO (ivacaftor/tezacaftor/elexacaftor) in combination with ivacaftor. The company said [...]

- Following positive Phase 1/2 results in Vertex's VX-880 program, Vertex and Lonza announce strategic manufacturing collaboration - - Dedicated large-scale facility will support commercial production of Vertex's T1D cell [...]

- First CRISPR gene-editing filings to be accepted for review by FDA - - FDA grants Priority Review for severe sickle cell disease (SCD) and Standard Review for transfusion-dependent beta [...]

-First and only CFTR modulator approved for this age group- BOSTON -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the U.S. Food and Drug Administration (FDA) approved KALYDECO([R])(ivacaftor) for use [...]

-About 900 children with cystic fibrosis will now have a medicine to treat the underlying cause of their disease for the first time- BOSTON -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) [...]

BOSTON -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that management will present at the Bank of America Securities 2023 Health Care Conference on Tuesday, May 9, 2023 at 9:20 [...]

-EU and UK filings completed in 2022; submissions validated by EMA and MHRA and the review procedure has begun as of January 2023- BOSTON & ZUG, Switzerland -- Vertex Pharmaceuticals [...]

- Vertex to initiate a Phase 1/2 clinical trial in the coming months - - VX-264 is the second investigational program in Vertex's pipeline containing stem cell-derived, fully differentiated pancreatic [...]

Massachusetts: Ropes & Gray has issued the following press release: Ropes & Gray represented ImmunoGen, Inc., a leader in the field of antibody-drug conjugates, in a global, multi-target license and [...]

ImmunoGen to Receive a $15 Million Upfront Payment; Eligible to Receive Up to $337 Million in Potential Option Fees and Milestone Payments Plus Tiered Royalties on a Per Target Basis [...]

BOSTON -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that management will present at Cowen's 43rd Annual Health Care Conference on Tuesday, March 7, 2023 at 2:50 p.m. ET. A [...]

BOSTON -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that management will present at the 41st Annual J.P. Morgan Healthcare Conference on Monday, January 9, 2023 at 11:15 a.m. ET/8:15 [...]

Boston, Massachusetts: Goodwin Procter LLP has issued the following press release: The Life Sciences team advised Entrada Therapeutics, Inc. (Nasdaq: TRDA) on its global collaboration with Vertex Pharmaceuticals Incorporated (Nasdaq: [...]

- Novel, inhaled mRNA therapy intended for the ~5,000 people with CF who cannot benefit from CFTR modulators - - VX-522 clinical trial in people with CF to initiate in [...]

- Oral presentation of encore clinical data from Phase 3 clinical trials of exa-cel - - Oral and poster presentations on quality-of-life impacts of sickle cell disease or transfusion-dependent beta-thalassemia [...]

- Entrada to receive $224 million upfront payment and $26 million equity investment, as well as potential milestone payments and royalties - - Global collaboration includes ENTR-701, Entrada's EEV-investigational candidate [...]

ImmunoGen, a company focusing on the expanding field of antibody-drug conjugates (ADCs), has reported a global, multi-target license and option agreement whereby it granted Vertex Pharmaceuticals (Vertex) rights to conduct [...]

M2 PRESSWIRE-November 15, 2022-: Sickle Cell Disease Pipeline Landscape Analysis: 40+ Key Players & 50+ Pipeline Drugs (C)1994-2022 M2 COMMUNICATIONS RDATE:14112022 DelveInsight's, 'Sickle Cell Disease Pipeline Insights, 2022' report provides [...]

BOSTON -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced its participation in the following upcoming investor conferences: * Jefferies London Healthcare Conference on Wednesday, November 16, 2022, at 9:10 a.m. [...]